Work

Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer

Year: 2017

Type: article

Abstract: Ann Oncol 2016; 27: 2032–2038 (doi:) In the original article, Figure 2 and Figure 3 legends referred to red curves instead of green curves. The legends have now been corrected. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancerAnnals of OncologyVol. 27Issue 11PreviewMethylnaltrexone (MNTX), a peripherally acting μ-opioid receptor (MOR) antagonist, is FDA-approved for treatment of opioid-induced constipation (OIC). Preclinical data suggest that MOR activation can play a role in cancer progression and can be a target for anticancer therapy. Full-Text PDF Open Archive

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx776

Authors: F. Janku, L.K. Johnson, D.D. Karp, J.T. Atkins, P.A. Singleton, J. Moss

Language: English

Topic: Cancer, Stress, Anesthesia, and Immune Response

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,080

Funder: National Institutes of Health